Abstract
Radiochemoresistance is considered the main cause of local recurrence and distant metastasis in lung cancer. However, the underlying mechanisms of radiochemoresistance remain to be uncovered. In this study, we determine the functions of cell cycle-related kinase (CDK20) in radiochemoresistance. CDK20 is a newly identified protein kinase, which plays critical roles in cell growth and proliferation in several types of cancer. Using tandem affinity purification technology, we provide evidences that CDK20 binds to the ubiquitin ligase Kelch-like ECH-associated protein 1 (KEAP1), which targets transcriptional factor nuclear factor erythroid-2-related factor 2 (NRF2) for degradation. We show that this interaction is mediated by an evolutionarily conserved ETGE motif on CDK20. Furthermore, we demonstrate that CDK20 competes with NRF2 for KEAP1 binding, enhances the transcriptional activity of NRF2 and lowers the cellular reactive oxygen species level. Moreover, CDK20-depleted cells display impaired cell proliferation, defective G2/M arrest and increased radiochemosensitivity in lung cancer. These phenotypes induced by CDK20 knockdown are partially dependent on NRF2 inactivation. More importantly, CDK20 is overexpressed in human lung cancer tissues, as determined by immunostaining. Collectively, our results suggest that CDK20 positively modulate the KEAP1–NRF2 cytoprotective pathway to regulate tumor progression and radiochemoresistance, implying that CDK20 is a novel, promising therapeutic target for lung cancer.
Similar content being viewed by others
References
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
Addario BJ . Lung cancer is a global epidemic and requires a global effort. Ann Transl Med 2015; 3: 26.
Herbst RS, Heymach JV, Lippman SM . Lung cancer. N Engl J Med 2008; 359: 1367–1380.
Mikell JL, Gillespie TW, Hall WA, Nickleach DC, Liu Y, Lipscomb J et al. Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. J Thorac Oncol 2015; 10: 462–471.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351–360.
Mitsuishi Y, Motohashi H, Yamamoto M . The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2012; 2: 200.
Jaramillo MC, Zhang DD . The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013; 27: 2179–2191.
O'Connell MA, Hayes JD . The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans 2015; 43: 687–689.
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S . Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196–5203.
Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004; 114: 1248–1259.
McMahon M, Itoh K, Yamamoto M, Hayes JD . Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003; 278: 21592–21600.
Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130–7139.
Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006; 3: e420.
Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010; 9: 336–346.
Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J et al. An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012; 53: 807–816.
Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009; 11: 1275–1276.
Malumbres M . Cyclin-dependent kinases. Genome Biol 2014; 15: 122.
Liu Y, Wu C, Galaktionov K . p42, a novel cyclin-dependent kinase-activating kinase in mammalian cells. J Biol Chem 2004; 279: 4507–4514.
Wohlbold L, Larochelle S, Liao JC, Livshits G, Singer J, Shokat KM et al. The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle 2006; 5: 546–554.
Tian Y, Wan H, Tan G . Cell cycle-related kinase in carcinogenesis. Oncol Lett 2012; 4: 601–606.
Ng SS, Cheung YT, An XM, Chen YC, Li M, Li GH et al. Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst 2007; 99: 936–948.
Feng H, Cheng AS, Tsang DP, Li MS, Go MY, Cheung YS et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest 2011; 121: 3159–3175.
Yu Z, Gao YQ, Feng H, Lee YY, Li MS, Tian Y et al. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut 2014; 63: 1793–1804.
Feng H, Yu Z, Tian Y, Lee YY, Li MS, Go MY et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J Hepatol 2015; 62: 1100–1111.
Wu GQ, Xie D, Yang GF, Liao YJ, Mai SJ, Deng HX et al. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. Int J Cancer 2009; 125: 2631–2642.
An X, Ng SS, Xie D, Zeng YX, Sze J, Wang J et al. Functional characterisation of cell cycle-related kinase (CCRK) in colorectal cancer carcinogenesis. Eur J Cancer 2010; 46: 1752–1761.
Xu S, Li X, Gong Z, Wang W, Li Y, Nair BC et al. Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration. Mol Cell Proteomics 2014; 13: 2986–3000.
Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68: 1303–1309.
Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009; 15: 3423–3432.
Chio II, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W et al. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 2016; 166: 963–976.
Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L et al. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res 2013; 73: 4406–4417.
Zhou S, Ye W, Shao Q, Zhang M, Liang J . Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol 2013; 88: 706–715.
Bai X, Chen Y, Hou X, Huang M, Jin J . Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev 2016; 48: 541–567.
Zhan L, Zhang H, Zhang Q, Woods CG, Chen Y, Xue P et al. Regulatory role of KEAP1 and NRF2 in PPARgamma expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med 2012; 53: 758–768.
Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 2012; 32: 1506–1517.
Yang Y, Roine N, Makela TP . CCRK depletion inhibits glioblastoma cell proliferation in a cilium-dependent manner. EMBO rep 2013; 14: 741–747.
Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010; 16: 3743–3753.
Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009; 36: 131–140.
Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA et al. Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein. J Biol Chem 2012; 287: 6539–6550.
Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213–223.
Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res 2013; 73: 2199–2210.
Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008; 68: 7975–7984.
Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene 2011; 30: 2219–2229.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81301719 to SX), Open Funds of State Key Laboratory of Oncology in South China (HN2014-10 to SX), a grant from the Wuhan Science and Technology Bureau (2015060101010041 to SX), the National Natural Science Foundation of China (81372435 to KY) and Department of Defense Era of Hope research scholar award (W81XWH-09-1-0409 to JC).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Wang, Q., Ma, J., Lu, Y. et al. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. Oncogene 36, 5321–5330 (2017). https://doi.org/10.1038/onc.2017.161
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2017.161
- Springer Nature Limited
This article is cited by
-
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Journal of Cancer Research and Clinical Oncology (2023)
-
NFR2/ABC transporter axis in drug resistance of breast cancer cells
Molecular Biology Reports (2023)
-
Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice
Cardiovascular Drugs and Therapy (2022)
-
Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1
Nature Communications (2021)
-
UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance
Cell Death & Differentiation (2021)